Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S A ScheyA G Dalgleish

Abstract

To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma. Twenty-four relapsed or refractory patients were treated with a dose-escalating regimen of oral CC-4047. Clinical responses and adverse effects were identified, and peripheral T-cell subsets, serum cytokines, and proangiogenic factors were evaluated. CC-4047 was tolerated with no serious nonhematologic adverse events. All patients were eligible for analysis. Toxicity criteria during the initial 4 weeks of study were used to define the maximum-tolerated dose (MTD). During this period, one patient withdrew with a deep vein thrombosis (DVT) probably caused by an undiagnosed primary melanoma with lymphadenopathy in the groin, one patient withdrew because of progressive disease (PD), and three patients discontinued with neutropenia. Nineteen of 24 patients continued on treatment beyond 4 weeks to PD or development of a serious adverse event. Three further patients developed a DVT at 4, 9, and 11 months. Treatment resulted in a greater than 25% reduction in paraprotein in 67% of patients, 13 patients (54%) experienced a greater than 50% reduction in paraprotein, and four (17%) of 2...Continue Reading

References

Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Oct 1, 1993·The Journal of Experimental Medicine·M J BrundaM K Gately
Jun 1, 1993·The Journal of Experimental Medicine·A L MoreiraG Kaplan
Aug 6, 1998·The Journal of Clinical Investigation·J A GollobJ Ritz
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Sep 1, 2001·Clinical and Experimental Immunology·M A FrassanitoF Dammacco
Dec 1, 2001·Expert Opinion on Biological Therapy·J B MarriottA G Dalgleish
May 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Keith DredgeAngus G Dalgleish
Jun 5, 2002·Blood·Eleonora UrbauerJohannes Drach
Nov 1, 2002·Current Opinion in Oncology·Noopur Raje, Kenneth C Anderson
Jun 5, 2003·Anti-cancer Drugs·Keith DredgeJ Blake Marriott
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jul 10, 2003·Hematology·S A Schey

❮ Previous
Next ❯

Citations

Nov 15, 2008·Cancer Immunology, Immunotherapy : CII·Christine GalustianAngus G Dalgleish
Jan 5, 2006·Annals of Hematology·Michael A Morgan, Christoph W M Reuter
Aug 10, 2012·Cancer Chemotherapy and Pharmacology·Matthew M CooneyAfshin Dowlati
Dec 4, 2012·Cancer Chemotherapy and Pharmacology·Matthew HoffmannGondi Kumar
Apr 4, 2009·Targeted Oncology·Efstathios KastritisMeletios A Dimopoulos
May 5, 2005·Current Treatment Options in Oncology·Sundar Jagannath
Nov 20, 2008·Current Treatment Options in Oncology·Peter H Wiernik
Apr 29, 2010·Current Hematologic Malignancy Reports·Jonathan KaufmanSagar Lonial
Apr 29, 2010·Current Hematologic Malignancy Reports·Ruben A Mesa
Feb 18, 2011·Current Hematologic Malignancy Reports·Martha Q Lacy
Aug 27, 2013·Current Hematologic Malignancy Reports·Jason P Meadows, Tomer M Mark
Dec 17, 2009·Medical Oncology·Sagar Lonial
Apr 11, 2013·Drugs·Shelley Elkinson, Paul L McCormack
Sep 7, 2013·The Lancet Oncology·Xavier Leleu
Sep 10, 2013·Blood Cancer Journal·A A Chanan-KhanM Q Lacy
May 15, 2012·Bone Marrow Transplantation·Y P L LinharesR P Gale
Nov 6, 2010·Leukemia·K H BegnaA Tefferi
Nov 3, 2005·Nature Clinical Practice. Oncology·Shaji Kumar, Kenneth C Anderson
Apr 28, 2011·Nature Reviews. Clinical Oncology·S Vincent Rajkumar
Oct 9, 2013·Nature Reviews. Clinical Oncology·Ravi Vij
Mar 31, 2007·Nature Reviews. Drug Discovery·Matthew Strobeck
Sep 5, 2007·Bone Marrow Transplantation·M S RaabK C Anderson
Jul 17, 2013·Proceedings of the National Academy of Sciences of the United States of America·Chris MahonyNeil Vargesson
Oct 16, 2007·Current Opinion in Hematology·Willem J van HeeckerenScot C Remick
Dec 13, 2006·TheScientificWorldJournal·Janice Jin HwangKenneth C Anderson
Sep 17, 2005·Acta Haematologica·J Anthony ChildSteve Schey
Dec 8, 2007·The Journal of Clinical Investigation·Laure A Moutouh-de ParsevalKyle Chan
Dec 17, 2009·Hematology·A Keith Stewart
Jan 18, 2011·Hematology·Sagar Lonial
Dec 6, 2012·Experimental Hematology & Oncology·Tahir LatifSaad Z Usmani
Oct 6, 2010·Future Oncology·Angus Dalgleish, Christine Galustian
Jul 11, 2013·Future Oncology·Peter A Forsberg, Tomer M Mark
Sep 13, 2014·Hematology/oncology Clinics of North America·Silvia Gentili, Sagar Lonial
Mar 26, 2011·Journal of Gastroenterology·Ming Jen TsaiTed H Chiu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.